This volume presents a multi-faceted view of the set of problems that the electronic industry currently faces in the development and integration of complex heterogeneous systems (including both hardware and software components). It analyses and proposes solutions related to the provision of integration platforms by SoC and IP providers in light of the needs and requirements expressed by the system companies: they are the users of such platforms which they apply to develop their next generation products. Further, the book tries to draw a comprehensive picture of the current interfaces between the platform providers and users, defined by technical requirements, current design methodology and flows, standards, and finally by the business context and relationships (which should not to be underestimated).

This book makes a significant contribution to the literature on strategy, management and innovation by drawing together the literature from these three fields and closely examining a critical issue, the importance of a firm's national base at a sectoral level in an era of globalization. Differences in national economic structures, management, firm learning, and firm strategy all contribute profoundly to competitive success. By examining two very dynamic high-technology industries--semiconductors and liquid crystal displays, the author shows how national systems of innovation are of critical importance in determining competitive success.

The economic boom of the 1990s that led to the rapid rise of computer hardware and software companies (on both sides of the Pacific Rim) also led to the rise of a trans-Pacific commuter culture, a culture in which thousands of Taiwanese-born high-tech engineers realized that they could greatly increase their career opportunities by establishing a life-style that allowed them and their families to regularly commute between two hornes, one in Silicon Valley and the other in Taiwan. The Global Silicon Valley Home takes a close look at how participants in the jet-set, wired-to-the-Net, trans-Pacific commuter culture have invented new ways of thinking about how their homes reflect their personal identities.

How did Japanese companies, technology-supporting organizations, and governments reformulate organizational strategies, industrial structures, and institutions to revive Japanese high-tech industries (semiconductor, telecommunications, and biotechnology) in the 1990s? This book takes a comprehensive look at the question by integrating the fields of institutional economics and corporate strategy, an approach that will be of significant interest theoretically and empirically to scholars, professionals, and graduate students. Complex interactions among diverse technology-related actors are presented, focusing on co-evolution among market changes induced by technology innovation, macro-level institutional arrangements for innovation, and corporate strategies for survival. Insights are provided on diverse types of institutional arrangements, technology innovation policies, and management practices for companies and technology organizations.

Financial Times Business Top Title March 2022 How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries? Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.

Describes principles and methodologies necessary to build efficient and highly productive work systems in high tech organizations that must develop and deploy new products in a timely fashion with competitive advantage. Presents techniques applicable to small high tech consumer products or large complex systems requiring cost control, waste minimization and rapid product development. Stresses methodologies to be used for strategic advantage. Suggests diverse strategic plans and their pros and cons, depending on the product and markets.

There are 17 million small and medium-sized enterprises (SMEs) in the European Union which play an important role in economic life. Within this subset, increasing recognition is being given to "new technology-based ftrms. " 1 In the literature, different defmitions have been put forward to describe the term new technology-based ftrm (Oakey et a11988; Roberts 1991; Autio 1995; Storey and Tether 1998). Common denominators include that the activity is based on the exploitation of advanced technological know-how, the prior affiliation of founders with research establishments and the entrepreneurial character of the ftrm. Research studies in Europe, North America and the Paciftc Rim have identifted these ftrms' important contributions in new employment creation, export sales growth, product and process innovation and structural adjustment (e. g. Rothwell & Zegveld 1982; OECD 1986; Oakey et a11988; Acs & Audretsch 1991; Roberts 1991; Coopers & Lybrand 1996). While there is a growing body of literature on new technology-based ftrms that concentrates on strategic issues such as access to fmancial resources, growth processes and innovation behaviour (see Storey and Tether 1998, for a review), there has been relatively little research into the process by which young high technology companies have internationalised. Research activity in the latter fteld has historically been strongly oriented towards large ftrms or, more rarely, towards "traditional transnational SMEs" in the manufacturing sector that often act as suppliers of bigger ftrms and are characterised by simple production technologies and low-technology products (United Nations 1993)."

This is the first book to comprehensively record the authors authoritative knowledge and practical experience of IC manufacturing, including the tremendous developments of recent years. With its strong application orientation, this is a must-have book for professionals in semiconductor industries.

Biotechnology is a field that inspires complex legal and ethical debates on an international scale. Taking a fresh approach to the subject, Matthias Herdegen provides a comprehensive assessment of the regulation of biotechnology processes and products from an international and comparative perspective. Herdegen explores how regulatory approaches to controversial issues such as: stem cell research and cloning and gene therapy differ across jurisdictions due to conflicting values and risk perceptions. The book goes on to examine how international regulatory instruments aim to address these conflicting perspectives and provide judgments based on broad international consensus. Chapters explore the interaction between biotechnology and different fields of law including: human rights, intellectual property, trade law and environmental law. In doing so, a number of complex issues are raised such as the need to balance commercial interests with socio-cultural considerations and the need to ensure respect for human dignity in the pursuit of biomedical research. Providing a concise and accessible guide to a complex field of international law, this book will be of great value to those researching the law and regulation of biotechnology, biomedicine and biodiversity both within the EU and on an international scale. The book will also be a useful resource for practicing lawyers as it includes sources from a diverse range of legal systems and analyses relevant decisions by international adjudicatory bodies.

Technology-based firms contribute to dynamic competition, ensure product variety, close market gaps and promote job creation. Their development is impeded by a difficult access to capital, high R&D costs and management deficits. The book analyses their chances and risks in the innovation process. Topics deal with the management of technology-based firms, different aspects on their financing, the spectrum of public promotion programmes and the venture capital market in Germany. Finally, the book centres on regional technology and economic promotion and the creation of regional networks for technology-based firms. The reader documents research of Fraunhofer-ISI on technology-based firms and their environment and aims at a better understanding of specific chances and risks in the development process of such firms.

Japan is an example of what is known as a "latecomer" in industrial development. Drawing on case studies of computer and telecommunications and related firms, Donna Doane investigates how intra- and inter-industry cooperation between public and private enterprises pushed rapid technological advancement in Japan. The book places such interlinkage in the context of a historical evolution, starting with prewar industrial house groupings that helped link indigenous and external ideas and form an integrated technological base.Doane focuses mainly on the postwar, catch-up period from the 1960s through the 1980s in which three characteristics associated with late development are examined: multistructured industry, family-based industrial networks, and a distinct government-industry relationship. Implications of the cooperative structure are drawn for other advanced industrial as well as developing countries, where flexible technological networks could help individual enterprises overcome the limitations of isolated organization to survive rapid economic changes.

A New York Times bestseller.

Winner of the Financial Times/McKinsey Business Book of the Year Award.

'Chilling . . . Reads like a West Coast version of All the President’s Men.' New York Times Book Review

The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.

In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.

Now to be adapted into a film, with Jennifer Lawrence to star.

The aim of this study is to investigate in the role of Venture Capital in the development of New Technology Based Firms in two countries: USA and Germany. Based on literature review and empirical work issues concerning the extent and stage of financing, the nature of oversight provided by Venture Capitalists and the framework conditions for Venture Capital are subject of investigation. The results have been reflected in a workshop with experts from research, industry and policy.

Global competitiveness has always been a hotly debated issue, promoting differing opinions among economists, management strategists, business leaders, and policy analysts and consultants. Global Economic Competition provides a broad framework to compare the United States economy with 23 other global economies. This is done by presenting empirical evidence in a series of comparative analyses of economic competition using data pertaining to specific countries, industries and companies. In this volume, the electronics industries are used to illustrate an ongoing economic warfare among competing regions, nations, and cluster companies across the electronic technology chain. Employing the latest empirical data to evaluate the competitiveness of the US economy and its electronic industries and companies in the 1980s and early 1990s, Global Economic Competition will be of interest not only to those who study economics, management science and international trade, but also to policy makers and business leaders.

The life sciences is an industrial sector that covers the development of biological products and the use of biological processes in the production of goods, services and energy. This sector is frequently presented as a major opportunity for policy-makers to upgrade and renew regional economies, leading to social and economic development through support for high-tech innovation. Innovation, Regional Development and the Life Sciences analyses where innovation happens in the life sciences, why it happens in those places, and what this means for regional development policies and strategies. Focusing on the UK and Europe, its arguments are relevant to a variety of countries and regions pursuing high-tech innovation and development policies. The book's theoretical approach incorporates diverse geographies (e.g. global, national and regional) and political-economic forces (e.g. discourses, governance and finance) in order to understand where innovation happens in the life sciences, where and how value circulates in the life sciences, and who captures the value produced in life sciences innovation. This book will be of interest to researchers, students and policy-makers dealing with regional/local economic development.

The incredible progress in microelectronics over the last 20 years has led to a whole range of products that have invaded and often reshaped our lives. Technologies currently being deployed or in the laboratory, such as the information super highway, virtual reality, instantaneous language translators and artificial nerves promise to further revolutionise our lives. This book, written by a distinguished member of the microelectronics community in collaboration with a leading journalist, seeks to bridge the gap between the microelectronics community and the general public. The evolution of the technology is explained with its social and economic effects, showing the forces shaping the industry and concluding with a glimpse of the ideas currently under development in the worlds' electronics laboratories.

Examining the dynamics of competence-building processes at the firm level, this book looks at a sample of Japanese and European companies engaged in the field of optoelectronics. The concept was derived from the notion of firm-specific competences which are closely related to the firm's intangible assets and accumulated technological bases. Several factors affect the rate and direction of competence-building, chief among them being primary markets, top management strategy and the evolution of research and development organization, and organizational learning. The book also introduces a technique to assess competences using three types of data on US patenting, scientific publications and qualitative interview data.

A series of biotechnology entrepreneurs - from the USA, the UK and continental Europe - tell their own stories of how they played a part in the evolution of the biotechnology companies they founded and/or now run. This book also looks at the role of venture capital and other forms of financing through their key stages of growth. A detailed introduction outlines the emergence of the biotech boom and its progress to date. This book is designed to be of interest to students of business. Stephanie Jones is the author of "The Headhunting Business" and "Working for the Japanese".

During the 1970s, Japan supplanted the United States as the world leader in steel production, automobile manufacturing, and consumer electronics. Are the Japanese poised to repeat these successes in the semiconductor industry? This question has vast potential significance, because semiconductor technology holds the key to competitiveness in high technology, one of America's last bastions of industrial supremacy. This book, the product of years of joint research by a multidisciplinary team of American and Japanese scholars, analyzes the strengths and weaknesses of each country's semiconductor industry with reference to three major areas: technological innovation; the role of government, not only in specific policies directed toward the semiconductor industry, but also in the broader context of industrial policy, government-business relations, and the two political systems; and the influence of financial institutions, ties between banks and businesses, and corporate financing. The book provides, in short, a broad yet in-depth analysis of emerging industrial competition in high technology between the world's two largest market economies. This is the first book in the series ISIS Studies in International Policy, sponsored by the International Strategic Institute at Stanford.

Ever since Schumpeter's groundbreaking work there has been a plethora of new research seeking to extend the direction and dynamics of innovation. Using a rich account of detailed interviews, this book offers new evidence on how latecomers have successfully caught up and leapfrogged incumbent firms. Catching Up and Leapfrogging: the new latecomers in the integrated circuits industry explores how technological transitions affect latecomer catch-up strategies, and vice versa, in a high technology industry. It looks to the East Asian latecomers who, towards the end of the twentieth century, pioneered a new pathway through organizational change by specializing in the key production stages of integrated circuits and pushing technologies further. This volume assesses how latecomer resource acquisition strategies have varied alongside structural industry changes and evaluates the mechanisms through which firms started life as technology followers and rose to become technology leaders. Xiao-Shan Yap and Rajah Rasiah present a unique story about how firm strategies evolve from the catching up phase to the leapfrogging phase, captured from the accounts of managers on the ground. It is the first time firm-level strategies have been systematically analysed to describe twenty-first century strategic management in the integrated circuits industry in particular, and the high tech industry in general. The evidence and analysis in this book offers insights for chief executive officers, policy-makers and researchers to revisit existing approaches to the theory of catching up and leapfrogging.

The life sciences is an industrial sector that covers the development of biological products and the use of biological processes in the production of goods, services and energy. This sector is frequently presented as a major opportunity for policy-makers to upgrade and renew regional economies, leading to social and economic development through support for high-tech innovation. Innovation, Regional Development and the Life Sciences analyses where innovation happens in the life sciences, why it happens in those places, and what this means for regional development policies and strategies. Focusing on the UK and Europe, its arguments are relevant to a variety of countries and regions pursuing high-tech innovation and development policies. The book's theoretical approach incorporates diverse geographies (e.g. global, national and regional) and political-economic forces (e.g. discourses, governance and finance) in order to understand where innovation happens in the life sciences, where and how value circulates in the life sciences, and who captures the value produced in life sciences innovation. This book will be of interest to researchers, students and policy-makers dealing with regional/local economic development.

"Free as in Freedom" interweaves biographical snapshots of GNU project founder Richard Stallman with the political, social and economic history of the free software movement. It examines Stallman's unique personality and how that personality has been at turns a driving force and a drawback in terms of the movement's overall success.

"Free as in Freedom" examines one man's 20-year attempt to codify and communicate the ethics of 1970s era "hacking" culture in such a way that later generations might easily share and build upon the knowledge of their computing forebears. The book documents Stallman's personal evolution from teenage misfit to prescient adult hacker to political leader and examines how that evolution has shaped the free software movement. Like Alan Greenspan in the financial sector, Richard Stallman has assumed the role of tribal elder within the hacking community, a community that bills itself as anarchic and averse to central leadership or authority. How did this paradox come about? "Free as in Freedom" provides an answer. It also looks at how the latest twists and turns in the software marketplace have diminished Stallman's leadership role in some areas while augmenting it in others.

Finally, "Free as in Freedom" examines both Stallman and the free software movement from historical viewpoint. Will future generations see Stallman as a genius or crackpot? The answer to that question depends partly on which side of the free software debate the reader currently stands and partly upon the reader's own outlook for the future. 100 years from now, when terms such as "computer," "operating system" and perhaps even "software" itself seem hopelessly quaint, will Richard Stallman's particular vision of freedom still resonate, or will it have taken its place alongside other utopian concepts on the 'ash-heap of history?'

Everything you need to know about the most important trend in the history of the world

Within most people's lifetimes, the developments in the biotechnology sector will allow us to live increasingly long and healthy lives, as well as provide us with technological innovations that will transform the way we live. But these innovations offer more than just hope for a better life, but hope for better returns too. Financial returns of incredible magnitude await savvy investors and businesspeople who can see the massive changes on the horizon. This book details these fast-moving trends and innovations and offers extensive advice on how to profit from them in business and investing.

An authoritative collection of the leading critical and contemporary writings published in the field of technology and organizations, this set spans a key fifty-year period. The volumes take the reader from the first and most influential papers from the early 1950s, through to recent publications which address contemporary and emerging debates in the field at the dawn of a new century.
Each of the 4 volumes has a particular focus upon this key area of research and scholarship:
* the early debates
* theories, paradigms and concepts
* critical empirical studies
* emerging themes and future debates
The editors provide an original introduction to, and overview of, the themes, debates, perspectives, theories and paradigms which characterise this key area of organisation studies. An extensive index guides the reader through the four volumes.